CPT1B and prostate carcinoma: Gene expression analysis showed that in more than 50% of the prostate cancer patient samples CPT1B enzyme mRNA, a rate limiting enzyme involved in the β-oxidation of FA, was elevated [44] and proposed that FAO is a prominent oncobioenergetic pathway in prostate cancer [26].